“…The final selection yielded 23 meta-analyses to be included for the main analysis. 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 50 , 52 , 53 , 61 , 62 , 63 Fig. 1 Flow diagram of the study selection process .…”
Section: Resultsmentioning
confidence: 99%
“…One non-significant association with high quality evidence was observed for 4 days-48 weeks IF than non-intervention diet for liver stiffness. 63 Three associations (two significant and one non-significant) conducted on participants with normal weight, mildly obesity, overweight or obesity, T2DM, or metabolic syndrome, compared non-intervention diet or normal diet, reporting moderate evidence on Serum AST, Serum ALT, testosterone. 34 , 63 Two non-significant associations with very low quality evidence were observed for 2–39 weeks IF than CER for prospective food consumption.…”
“…The final selection yielded 23 meta-analyses to be included for the main analysis. 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 50 , 52 , 53 , 61 , 62 , 63 Fig. 1 Flow diagram of the study selection process .…”
Section: Resultsmentioning
confidence: 99%
“…One non-significant association with high quality evidence was observed for 4 days-48 weeks IF than non-intervention diet for liver stiffness. 63 Three associations (two significant and one non-significant) conducted on participants with normal weight, mildly obesity, overweight or obesity, T2DM, or metabolic syndrome, compared non-intervention diet or normal diet, reporting moderate evidence on Serum AST, Serum ALT, testosterone. 34 , 63 Two non-significant associations with very low quality evidence were observed for 2–39 weeks IF than CER for prospective food consumption.…”
“…This self-cleansing mechanism is thought to play a role in preventing the accumulation of cellular waste and potentially reducing the risk of age-associated diseases. Additionally, fasting periods might lead to the upregulation of certain genes associated with longevity and stress resistance (Lange, et al, 2023).…”
The aging process is inherently linked to an increased susceptibility to various chronic conditions, such as cardiovascular diseases, diabetes, and neurodegenerative disorders. The aim of this research is to delves into the current body of knowledge surrounding intermittent fasting and its potential implications in preventing age-related diseases. The methodological approach used in this research is systematic review. Research search using PRISMA strategy by searching journal articles from various databases including Scopus, Proquest, Science Direct, CINAHL, and Google Scholar in the last five years from 2019 to 2023. The results of PRISMA found 333 articles identified through the five databases contained in research methods and screened through titles. Result this research is the promising role of intermittent fasting in promoting anti-aging effects and preventing age-associated diseases through its multifaceted influence on cellular and molecular mechanisms. As an innovative avenue, intermittent fasting holds the potential to revolutionize strategies aimed at enhancing healthy aging and longevity.
intermittent fasting as new approaches as anti aging for preventing age-associated diseases
“…The umbrella term, intermittent fasting, comprises various approaches such as alternate‐day fasting, time‐restricted‐feeding, and the 5:2 diet 51 . While intermittent fasting induces weight loss in obesity, T2D 76 and MASLD, 77 also improving serum lipids and liver stiffness, 43,51,78‐85 its efficacy on weight loss is not superior to continuous energy restriction 86 . Studies on other nutritional modifications based on, e.g.…”
SummaryBackgroundThe current obesity pandemic has given rise to associated comorbidities and complications, including type 2 diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). During the last decade, certain glucagon‐like peptide 1 receptor agonists (GLP‐1RA), originally developed as antihyperglycemic drugs, also demonstrated efficacy for weight loss.AimsTo review shared pathophysiologic features of common metabolic diseases and compare therapeutic strategies to reduce body weight and related complications.MethodsWe performed an extensive literature research to describe the effects of lifestyle modification, first‐generation anti‐obesity drugs, and GLP‐1RA on weight loss in humans with obesity, type 2 diabetes and MASLD.ResultsUntil recently, treatment of obesity has been limited to lifestyle modification, which offer moderate degree and sustainability of weight loss. The few approved first‐generation anti‐obesity drugs are either limited to short term use or to certain forms of obesity. Some GLP‐1RA significantly decrease caloric intake and body weight. Liraglutide and semaglutide have therefore been approved for treating people with obesity. They also lead to a reduction of hepatic fat content and inflammation in people with biopsy‐confirmed MASLD. Possible limitations comprise adverse effects, treatment adherence and persistence.ConclusionCertain GLP‐1RA are superior to lifestyle modification and first‐generation anti‐obesity drugs in inducing weight loss. They have therefore markedly changed the portfolio of obesity treatment with additional beneficial effects on steatotic liver disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
